Annovis Bio (ANVS) Total Non-Current Liabilities (2019 - 2026)
Annovis Bio (ANVS) posted Total Non-Current Liabilities of $12.8 million for Q1 2026, up 251.84% sequentially from $3.6 million in Q4 2025, and up 410.73% YoY from $2.5 million in Q1 2025.
Annovis Bio (ANVS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Annovis Bio has reported Total Non-Current Liabilities for 5 years, with the latest figure at $12.8 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 410.73% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 410.73% YoY) and the FY2025 annual result came in at $3.6 million, down 6.33% from the prior year.
- Total Non-Current Liabilities climbed to $12.8 million in Q1 2026 per ANVS's latest filing, from $3.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $12.8 million in Q1 2026 and troughed at $2.5 million in Q1 2025.
- A 4-year average of $5.2 million and a median of $4.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities plunged 55.42% in 2025, then surged 410.73% in 2026.
- Over 4 years, Total Non-Current Liabilities stood at $4.3 million in 2023, then decreased by 9.3% to $3.9 million in 2024, then slipped by 6.33% to $3.6 million in 2025, then jumped by 251.84% to $12.8 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $12.8 million, $3.6 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 6.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.79 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 2.81 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 6.86 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 4.87 Mn |
| Dec 31, 2023 | 4.28 Mn |
| Dec 31, 2019 | 605,807.00 |